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1. Introduction
Rectal cancer continues to affect many patients in the United States and world-wide. For
instance, in 2012, rectal cancer affected 40,290 Americans [1]. Patients affected with rectal
cancer who have a clinical stage II (T3-T4, NO, MO) or III (Any T, N1-N3, M0) tumor are treated
with pre-operative chemoradiation (CRT) followed by surgical intervention [total mesorectal
excision (TME)]. In up to 40% of patients treated with CRT, the tumor becomes clinically
undetectable (cCR) [2]. Clearly, this is a desirable outcome in oncology. Adding novel
radiosanitizing agents, prolonging the period from CRT to TME, increasing the radiation dose,
adding chemotherapy before CRT are few modalities that have been investigated to increase
the number of patients achieving a complete response. The following chapter reviews current
strategies in recent attempts at maximizing the ratio of patients who achieve a cCR. Current
margins are resection following TME in the era of CRT are also reviewed.
2. Recent status of pre-operative biomarkers to determine a response to
neoadjuvant chemoradiation
Neoadjuvant chemoradiation for the management of patients with stage II and III rectal cancer
results in a clinical complete response (cCR), the absence of detectable rectal tumor with
diagnostic modalities [i.e. endorectal ultrasound (EUS), magnetic resonance imaging (MRI),
digital rectal exam (DRE), or proctoscopy], in 10-40% of patients [2].
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The fundamental pre-clinical and clinical question is to determine whether there are markers
that can detect tumors that will respond well to neoadjuvant treatment such that these patients
could be potential candidates for observation without operative intervention. Conversely, if a
patient is not likely to respond to neoadjuvant chemoradiation, they should submit to surgical
intervention sooner. Therefore, a myriad of pathways and molecules ranging from DNA-repair
molecules to molecules that mediate cell cycle dynamics to apoptotic mediators as well as
hypoxic mechanisms have been investigated with a wide range of results, which are summar‐
ized by Ramzan et al [3]. Currently, there is no unifying pathway that can reliably predict
responses to chemoradiation in patients with rectal cancer.
2.1. DNA repair molecules
One of three pathways is responsible for the repair of DNA double-strand breaks (DSB)
induced by ionizing radiation: homologous recombination (HR), non-homologous end-joining
(NHEJ) pathway, or an alternate NHEJ pathway [3]. Of these, the non-homologous end-joining
(NHEJ) pathway is fundamental for DSB repair. The catalytic subunit of DNA-dependent
protein kinase (DNA-PKcs) is an integral part of the NHEJ pathway. This mechanism can be
broadly classified into three steps: (1) Ku 70/80 heterodimer identifies DSB and stick to DNA
broken ends, facilitates the activation and recruitment of DNA-PKcs; (2) enzymatic processing
of the DNA ends; and (3) ligation by DNA ligase IV. Ku 70/80 proteins play a fundamental
role as they recruit DNA-PKcs which then set the cascade of DNA repair. Recent data dem‐
onstrate that DNA-PKcs and Ku proteins may have a central role in radiation induced cell
death and might predict the response to radiation. However this is an area that is still under
investigation.
2.2. Apoptosis
In the central mediators of apoptosis pathway in response to ionizing radiation, the initial
response begins with an up-regulation of p53 (Figure 1). p53 then directly activates the cyclin
dependent kinase inhibitors (such as p21). Cell cycle progression stops until the cell repairs
the damage induced by ionizing radiation. If the cell is unable to repair itself, it undergoes
apoptosis. The anti-apoptotic Bcl-2 inhibits p53, while p53 inhibits the inhibitor of apoptosis
(survivin). All of these molecules have been investigated to determine if their up-regulation
or down-regulation could predict a response to ionizing radiation. Mutations and manner of
detection have to be considered in these studies. Additionally, contrary to expectations, p21
or Bax deficient cells lead to a more radiosensitive rather than a more radioresistant phenotype
[4]. Thus, analyses of these molecules in predicting a response to ionizing radiation have been
largely unyielding [5].
A recent systematic review analyzing the role of p53 as a predictor of a response to ionizing
radiation included 30 studies of which 25 used p53 protein status, 7 used gene analysis
detection and two used both. The results revealed that patients that demonstrated a p53 wild-
type (and/or low expression) had a good response risk of 1.3 [CI=1.14 to 1.49], complete
response RR was 1.65 [CI=1.19 to 2.30] and poor response RR 0.85 [CI = 0.75 to 0.96] [6].
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Figure 1. Central mediators of apoptosis. Ionizing radiation (IR) leads to an increase of p53, which in turn activates p21
and causes cell cycle arrest. P53 also activates Bax, which results in apoptosis
2.3. Gene modifications and polymorphisms
It is possible that with standardized techniques, we might be able to utilize other molecules in
the apoptotic pathway alone or in combination to better predict neoadjuvant chemotherapeutic
responses in patient affected with rectal cancer. Another area that is gaining momentum is that
of epigenetic changes. For instance methylation of the retinoic acid receptor gene (RARB) and
the checkpoint with forkhead and ring finger gene (CHFR) discriminated between TI-2 vs. T2-3
un-irradiated tumors. RARB methylation was also associated with nodal metastasis and
lymphovascular invasion (LVI). Methylation of other genes have also predicted nodal
metastasis [7]. Thus, methylation can predict aggressiveness and in combination with the
mutation status of other molecules, a predictive panel of a response to ionizing radiation can
then be constructed. In a separate study, DNA analysis of biopsies of patients prior to radiation
demonstrated a gene mutation and two gene polymorphisims to be associated with resistance
to radiation as measured by pCR [8].
3. Novel strategies in neoadjuvant therapy for locally advanced rectal
cancer
The trimodal approach of neoadjuvant chemoradiotherapy and surgery is generally associated
with high rates of local-regional control for patients with locally advanced rectal cancer [9].
However, there is room for improvement in the oncologic outcomes of the most locally
advanced tumors, and also great interest in increasing the rate of complete pathologic
responses to chemoradiotherapy, which may allow for increased utilization of non-operative
management.
A variety of chemotherapy and targeted agents have been studied as part of novel neoadjuvant
regimens in an attempt to improve on results obtained with fluoropyrimidine-based chemo‐
radiation. Although early-phase studies have shown modest improvements in tumor respons‐
es; this has often been at the expense of increased toxicity.
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3.1. Oxaliplatin
There has been much interest in particular in the use of oxaliplatin concurrent with radiation.
The ACCORD 12/0405 PRODIGE 1 study randomized patients with locally advanced rectal
cancer to preoperative treatment with radiation (45 Gy in 25 fractions) plus capecitabine or
radiation (50 Gy in 25 fractions) plus capecitabine and oxaliplatin [10;11]. High-grade toxicity
rates were higher in the oxaliplatin-treated patients (25 versus 11%), and there were no
significant differences between the two arms with respect to rates of pCR, local control, and
overall survival. In the STAR-01 trial, over 700 patients with locally advanced rectal cancer
were randomized to neoadjuvant treatment with radiation (50.4 Gy total dose) plus infusional
5-FU with or without weekly oxaliplatin, followed by surgery [12]. The addition of oxaliplatin
increased the rate of high grade toxicity (24% versus 8%) but did not improve the pathologic
complete response rate (equal in the two arms at 16%). In the PETACC-6 trial, 1094 patients
with locally advanced rectal cancer were randomized to preoperative radiation plus capeci‐
tabine followed by surgery and adjuvant chemotherapy versus the same regimen with
oxaliplatin delivered during the chemoradiation course as well as the adjuvant course [13].
The use of oxaliplatin again increased toxicity rates, with no disease-free survival benefit.
The NSABP R-04 trial is a four-arm study that compared infusional 5-FU and capecitabine,
with and without the use of oxaliplatin, during neoadjuvant chemoradiotherapy for rectal
cancer [14]. Capecitabine in place of 5-FU yielded a different toxicity profile with similar rates
of pCR, local-regional control, and overall survival. Patients treated with oxaliplatin had
higher rates of high-grade toxicity without significant improvements in local-regional control
or overall survival. Finally, in the CAO/ARO/AIO-04 trial, patients with locally advanced rectal
cancer were randomized to treatment with radiation with concurrent 5-FU, surgery, and
adjuvant bolus 5-FU versus radiation plus 5-FU, oxaliplatin, surgery, and adjuvant mFOL‐
FOX6 [15]. There were no substantial differences in rates of pathologic complete response or
margin-negative surgery. However, 3-year disease-free survival was higher in the oxaliplatin
group (75.9% versus 71.2%). The independent contribution of the oxaliplatin delivered in the
neoadjuvant setting is unclear.
3.2. Targeted therapies
Incorporation of novel targeted drug agents into trimodality regimens is also an area of
dynamic clinical investigation. Bevacizumab is an anti-VEGF antibody. Willett et al. reported
on 32 patients who underwent one cycle of bevacizumab followed by radiation, infusional 5-
FU, further bevacizumab and subsequent surgery [16]. Local control was 100% at 5 years;
disease-free survival was 75% at 5 years. Landry et al. reported on the phase 2 ECOG 3204
study, which combined capecitabine, oxaliplatin, and bevacizumab for patients with operable
T3 and T4 rectal cancer [17]. Of the 49 patients who proceeded to surgery, 17% had a pathologic
complete response. Surgical complications were common and may have been related to the
addition of bevacizumab. Bevacizumab has also been associated with delayed wound healing
in other studies [18;19].
Work is also underway evaluating combinations of the anti-EGFR agents panitumumab and
cetuximab with chemoradiation. When combining such agents with conventional chemother‐
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apy and radiation therapy, appropriate sequencing of these treatments may be of critical
importance to optimize oncologic efficacy [17;20].
3.3. Novel scheduling modalities
A more recent area of clinical study has been to incorporate systemic therapy prior to chemo‐
radiation or to eliminate radiation as a component of neoadjuvant therapy for selected patients
with locally advanced disease (Figure 2). Chua et al. reported, on a phase 2 study, incorporating
induction chemotherapy prior to neoadjuvant chemoradiotherapy [21]. Patients had locally
advanced rectal cancers that were considered high-risk by MRI criteria (including tumors with
threatened mesorectal resection margin, extensive mesorectal fat involvement, and T4 and/or
N2 tumors). Patients were treated with 12 weeks of capecitabine and oxaliplatin. This was
followed by radiation (total dose of 54 Gy) and concurrent capecitabine for six weeks and
finally total mesorectal excision (Figure 2 B). One hundred and five patients were enrolled.
Twenty percent of the patients had a pathological complete response, and 3-year progression-
free and overall survival were 68% and 83% respectively. In a similar approach, a recent
randomized phase II trial incorporating induction capecitabine and oxaliplatin showed no
difference in histopathologic downstaging compared to patients treated with chemoradiation
alone [22]. The authors of these studies suggest that more data is needed before approaching
induction chemotherapy as a standard of care for high risk patients.
Schrag et al. recently reported on 32 patients with stage II or III rectal cancer treated with 6
cycles of FOLFOX, with bevacizumab delivered during cycles 1-4, without planned radiation
therapy (Figure 2 C) [23]. Thirty of the 32 patients proceeded to surgery without undergoing
preoperative irradiation. Of the 32 patients, 25% had a pathologic complete response. The 4-
year local recurrence rate was 0% and the 4-year disease-free survival rate was 84%. This
strategy of neoadjuvant chemotherapy without planned use of radiation therapy (without use
of bevacizumab) is under further study in the randomized N1048 study. However, these
studies are in the initial stages of assessment at this time.
A. Conventional tri-modality treatment for rectal cancer
Chemoradiation TME
B. Induction chemotherapy first
Chemotherapy Chemoradiation TME
C. Chemotherapy (no radiation)
Chemotherapy TME
Figure 2. Novel strategies in neoadjuvat therapy for local advanced rectal cancer. Conventional treatment (A). Induc‐
tion chemotherapy followed by chemoradiation (B). Elimination of radiation (C).
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4. What is the appropriate length of the “waiting period” between
completion of neoadjuvant chemoradiation and surgery?
Initially, the waiting period following CRT was based on sufficient time to allow the acute
radiation reaction to subside. Thus, an interval between 3-5 weeks was selected based on
empirical experience. Favorable outcomes in patients who achieve a pCR and the desire to
obtain a cCR have led to an increase of the radiation dose to the tumor center, increased
intervals between CRT and TME, addition of chemotherapy during the waiting time, or
starting with induction chemotherapy [24].
Allowing for a “waiting period” without active treatment of many weeks between the
completion of neoadjuvant long-course therapy and surgery is common in the management
of rectal cancer. Delaying surgery may allow for continued volume reduction of the treated
tumor, potentially increasing the ultimate likelihood of a sphincter-preserving surgery for low-
lying tumors and facilitating ease of the operation. However, too long of a delay in proceeding
to surgery, especially in patients with poor response to neoadjuvant treatment, may allow for
growth of the primary tumor with an increased risk of margin-positive surgery and increased
risk of distant dissemination of cancer [25]. Further, there is a perception that waiting too long
after the end of CRT (> 12 weeks) might lead to radiation fibrosis, making surgical intervention
more difficult. However, this has not been substantiated in the literature [24].
The Lyon R90-01 trial randomized patients with T2-3 (N-any) rectal carcinoma to treatment
with preoperative radiation (39 Gy in 13 fractions, without concurrent chemotherapy) followed
by either a “short interval” to surgery (surgery performed within 2 weeks of completion of
radiation) or a “long interval” to surgery (surgery performed within 6-8 weeks of completion
of radiation) [26]. Tumors had to be low enough in the rectum to be palpable on digital
examination. The primary endpoint of the study was the rate of sphincter-preserving surgery.
The decision regarding the type of surgery was made by the surgeon at the time of the
operation. Of the enrolled patients, 201 were assessable. Patients in the long-interval group
had improved clinical and pathologic responses compared to the short-interval group.
Twenty-six percent of the patients in the long-interval group had either a complete or near-
complete pathologic response compared to 10.3% in the short-interval group, likely a reflection
of the increased amount of time for lethally injured tumor cells to manifest their injury as death.
Ultimately, however, 75.5% of the patients in the long-interval group as opposed to 67.7% in
the short-interval group underwent a sphincter-preserving operation, a difference that was
not statistically significant. There were no differences in the post-operative toxicity and
mortality rates between the two groups. There were also no differences in overall survival or
local control rates to a median follow-up of 33 months.
Integrating systemic therapy during the waiting period may have potential benefits for
patients with rectal cancer, including improved downstaging of the primary tumor as well as
potentially more effective treatment (relative to delayed postoperative treatment) of distant
micrometastatic disease, a major cause of the poor disease-free survival rates seen in patients
with locally advanced rectal cancer. Garcia-Aguilar and colleagues performed a phased II non-
randomized trial investigating the use of chemotherapy with modified FOLFOX-6 delivered
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during the waiting period following standard long-course chemoradiotherapy, with succes‐
sively more administrations of chemotherapy (and thus longer overall waiting periods) [27].
In a preliminary analysis of patients treated with two cycles of mFOLFOX-6 during the waiting
period, with a mean time of 11 weeks from completion of neoadjuvant therapy to surgery, the
pathologic complete response was 25%. In a comparison group of patients treated with
neoadjuvant chemoradiation and no intervening systemic therapy, with a mean time to
surgery of 6 weeks, the pCR was 18%. There was no substantial difference between the two
arms with respect to postoperative complication rates.
In the large Dutch Surgical Colorectal Audit study including 1593 patients, patients were
divided into three groups in terms of interval from the start of CRT to TME: < 13, 13-14, and
15-16 weeks. The largest pCR (18%) was observed in patients in the 15-16 week group (median
time at the end of CRT = 9-10 weeks) [28].
A meta-analysis was conducted that compared two groups of patients: (1) less or equal to the
conventional 6-8 week period from CRT to surgery and (2) longer than 6-8 weeks. pCR was
the primary end point and was increased from 13.7 to 19.5% in the more than 8 week group
[29]. This study included 13 trials inclusive of 3584 patients. Secondary end points (OS, DFS,
R0 resection rates, sphincter preservation, and complication rates) were similar in both groups
[29]. However, in patients who had a short interval (< 1 week), the rate of perineal wound
complication and anastomotic leak was higher [29].
The question of appropriate waiting time periods has also emerged in the context of short
course radiation therapy (5 Gy X 5 fractions without concurrent chemotherapy). In the original
clinical trials of short-course neoadjuvant therapy, surgery was mandated to be performed
within one week of completion of radiation [30]. This regimen has been associated with lower
pCR rates relative to long-course neoadjuvant treatment, possibly as a result of the decreased
interval between radiation and surgery. In the more recent Stockholm III trial, patients were
randomized to one of three arms: short-course radiation followed by surgery within 1 week,
short-course radiation followed by surgery at 4-8 weeks, or long-course radiation (2 Gy X 25
fractions, without concurrent chemotherapy) followed by surgery at 4-8 weeks [31]. Interest‐
ingly, pCR rates were highest in the short-course radiation group with the extended interval
to surgery (12.5%, versus 0.8% in the short interval group and 5% in the long-course radiation
group). Patients treated with short-course radiation and delayed surgery had postoperative
complication rates that were similar to the two other groups. In an analysis of actual time to
surgery, patients treated with short-course radiation followed by surgery at an interval of 11-17
days had the highest rates of postoperative complications.
Many questions remain regarding the appropriate duration of the waiting period in patients
undergoing neoadjuvant therapy. Most of the data regarding CRT-TME gap emanate from
retrospective studies. Thus, the recommendations of the length of time are largely observa‐
tional and empirically-driven. However, cCR and pCR has been observed in three randomized
controlled trials when the gap is about 8-12 weeks [26;31;32]. Surgery within 3-4 weeks in the
long CRT modality should not be performed secondary to radiation reaction. There is currently
limited experience in waiting over 12 weeks.
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Integration of systemic therapy both during this time period as well as during the induction
phase (prior to chemoradiation) remain active areas of clinical interest. In addition, determin‐
ing which patients are made candidates for sphincter-preserving surgery also remains an
imprecise practice. Improvements in imaging technologies and possible use of pre-treatment
biomarkers may improve on patient selection for low anterior resection.
5. Current status of the role of non-operative management in rectal cancer
for patients with a complete clinical response
Neoadjuvant chemoradiation for the management of patients with stage II and III rectal cancer
results in a clinical complete response (cCR), which is defined as the absence of detectable
rectal tumor with diagnostic modalities [i.e. endorectal ultrasound (EUS), magnetic resonance
imaging (MRI), digital rectal exam (DRE), or proctoscopy] in 10-40% of patients [33]. Can these
patients be followed non-operatively?
There have been three sentinel papers that have addressed this issue: one in 2004 published
by Habr-Gama’s group [34], the second was a reproduction of these results by a Dutch group
in 2011 [35], which was followed by a systematic review by Glynne-Jones in 2012 [2]. An
editorial summarizes the main aspects of these seminal events [36].
The first manuscript to document a possible approach in observing patients that achieve a cCR
was published by Harb-Gama’s group in 2004. In this study, 71 patients who had a cCR were
compared to 22 patients that had an initial incomplete response, but after surgery, they were
found to have no microscopic evidence of tumor in the resected specimen (pCR). Patients who
underwent surgery had a 5-year overall survival of 88% compared to the cCR group, which
was 100%. Disease free survival was 83% in the surgery group and 92% in the cCR group [34].
Mass et al. documented similar observations in 2011 [34]. This study compared 21 patients
who had a cCR and compared them to 20 patients from another observational study that had
documented pCR. Only one patient developed a recurrence at a 2-year follow up and they
were all alive at this point in time. Comparatively, the 2-year disease free survival for patients
in the surgery group was 93% with an overall survival of 91%.
A number of small institutional studies have documented similar observations in small cohort
of patients such as in the United States [37] and in the United Kingdom [38] in 2012. A few
other papers that demonstrated similar findings was summarized by a systematic review by
Glynne-Jones in 2012 [2].
In this systematic review, 30 papers were included that met the primary end point of cCR with
secondary end points of local recurrence, overall survival and disease free survival. This
analysis demonstrated that 361 patients (56%) were from a single group (Habr-Gama) and the
rest (n=289) were from eight different groups. cCR ranged from 11% - 39%. Results of secondary
outcomes showed low local recurrence in Habr-Gama studies (~5%), but higher in all other
series 33.8% (range 23%-83%). Habr-Gama reported salvage surgery to be possible in most
cases, whereas only one quarter of patients could be salvaged surgically in all other groups.
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Long-term outcomes (DFS, and OS) in other groups were similar to Habr-Gama’s and
suggested that patients who achieve cCR have similar outcomes to patients who undergo
surgery and are found to have pCR.
The authors of the meta-analysis suggested that there is not enough evidence at this time to
support observation in patients who have a cCR [2]. The inability to propose non-operative
management for patients with a cCR primarily emanates from an inability to clearly define
cCR. However, it is likely that a group of patients with a cCR can be observed without surgery;
who those patients are and how we can monitor them closely is a difficult issue in the
management of rectal cancer.
6. Appropriate distal margins of resection in the era of neoadjuvant therapy
Following resection of the rectum, current standard procedure is examination of the distal edge
to ensure that the cells at this distal margin are free of any tumor characteristics. A positive
distal margin is an unequivocal indication for additional treatment as it signifies that the
resection has not been adequate.
This length from the tumor to the distal edge is of even greater importance when consider‐
ing those cancers occurring in the distal or lower portions of the rectum (close to the anal
sphincters).  In  treating  patients  with  lower  rectal  tumors,  a  balance  of  performing  an
oncologically  free  operation  versus  obtaining  proper  anal  sphincter  function  must  be
maintained.  There is  no question that  when it  comes to patient’s  preference,  an LAR is
always preferred to an APR [39-41].
Prior to the era of CRT, substantially large margins of resections were thought to be necessary.
A 5 cm margin was widely used, which emanated from studies showing this to result in
acceptable outcomes compared to those with greater than 5 cm distal margins [4-10]. In an
attempt to perform sphincter preservation operations, this number was rapidly challenged
and reduced to the point in which margins less than 5 cm became acceptable [42-47].
With the current tri-modality management of rectal cancer, a 2 centimeter margin has been
adopted with excellent oncologic outcomes [48-52]. In 2004, Habr-Gama published results of
observing patient who achieved a clinical complete response (cCR) following neoadjuvant
CRT [34]. This concept, in a way, challenged the need to obtain a large margin in patients with
low rectal tumors who have responded well to pre-operative treatment. Studies have emerged
that indicate that even a 1 cm distal margin is oncologically safe [40;48;49;52-58]. This has been
considered oncologically acceptable in the literature. The vast majority of work that has
examined the question of 1 cm margins has indicated that there is no statistically significant
difference in regards to survival or recurrence between groups of patients with margins greater
than 1 cm than those with margins less than or equal to 1 cm [40;48;49;52;54-58] Table 1.
More recently, the 1 cm margin has been challenged to be further reduced. Some surgeons have
suggested that sub-centimeter margins as small as 2 mm or 5 mm margins are also safe [54].
Recent Advances in the Management of Rectal Cancer 9
Paper 
% Patients with 
Neoadjuvant 
Chemoradiotherapy 
Number of local recurrences/ total patients 
by margin (%) P % Survival Years of Follow Up P 
  ≤ 1 cm > 1 cm   ≤ 1 cm > 1 cm   
Andreola et al (2001) 61 4/31 (12.9) 3/45 (6.6) 0.4407a         
Huh et al (2008) 100 1/18 (6) 0/25 (0) 0.058 71.3 81.3 5 years 0.27 
Kim et al (2009) 71.2 7/167 (4.2) 31/747 (4.1) 0.98         
Kiran et al (2011) 40 7/198 (3.5) 19/586 (3.2) 0.821a 67.4 66.5 5 years 0.77 
Kuvshinoff et al (2001) 100 1/16 (6) 0/12 (0)   53 85 4 years 0.06 
Moore et al (2003) 100 2/17 (12) 7/77 (9) 0.93 82 85 3 years 0.88 
Pricolo et al (2010) 100 0/10 (0) 0/23 (0)           
Rutkowski et al (2008) 100 4/42 (9.5) 17/122 (13.9) 0.597 65.6 68.7 5 years 0.66 
Total   22/464 (4.7) 72/1589 (4.5) 0.8995a         
 
A meta-analysis indicated a higher rate of anastomotic recurrence by only 1.6% in the <1cm
margin groups, but this small observed difference was not statistically significant. A systematic
review of the literature on sub-1 cm distal margins of resection found in only two papers a
possible adverse outcome associated with this smaller margin [54]. However, in these two
papers, the percentage of patients submitting to neoadjuvant CRT was less than 5% [59;60].
Distal margins of 8 mm or 5 mm have also been proposed [40;54;56;61], but there is currently
not enough data to draw definitive conclusions at this time. The results so far seem to point to
these margins also being oncologically safe. Published data on possible adverse oncologic
outcomes with 8 mm margins has been documented, but this has occurred in the absence of
neoadjuvant CRT [62]. In this case, margins below the 8 mm cutoff point were found to correlate
with a significantly higher rate of recurrence and lower rate of long-term survival. However,
when the same length of distal margin is evaluated within the context of neoadjuvant CRT, 8
mm margins have not been found to have adverse oncologic outcomes compared to patients
having more than 8 mm margins. In this study, the authors did find a higher rate of mucosal
recurrence in patients with less than 8 mm margins. They concluded that the probable cause of
a higher rate of mucosal recurrence was tumor shedding into the anastomosis [40].
Another study evaluated patients who had received neoadjuvant therapy with margins less
than or equal to 5 mm in regards to 5 year outcome and local recurrence [61]. There was no
difference in local recurrence 5 years after surgical intervention. This finding was echoed by a
number of similar studies [48;53;54;56] (Table 2). Additionally, a meta-analysis demonstrated
a small non-significant rate of anastomotic recurrence by 1.7% in the 5mm group, but again
this also was not statistically significant [54].
Paper Number of recurrences/ total patients by margin (%) P 
  ≤ 0.5 cm > 0.5 cm   
Kuvshinoff et al (2001) 1/9  (11) 0/19 (0)   
Kiran et al (2011) 2/25 (8) 9/164 (5.5) 0.41 
Rutkowski et al (2010) 3/29 (10.3) 10/231 (4.3) 0.166 
Total 6/63 (9.5) 19/414 (4.6) 0.123 
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It is important to keep in mind that in all of these retrospective studies, there is a clear aspect
of selection bias. Typically, patients that are selected for smaller margins are those that have
tumors that are expected to have more favorable outcomes. Low tumors, which have less
favorable predicted outcomes are usually treated with an abdominoperineal resection (APR),
a procedure that renders the question of margins moot [54]. This makes it difficult to properly
match patient populations being compared in these studies. It is also important to emphasize
that there is a lack of consistent methodology of measuring the distal margin across all studies.
Measurement of the distal margin is done in a variety of circumstances: pinned, unpinned,
fixed, immediately after sectioning, etc [54;63;64]. A lack of standardization is disadvantageous
to drawing a unified conclusion; however, the broad consensus that exists regardless of this
wide range of measurement techniques suggests that the conclusion is nonetheless valid.
Furthermore, while the surgical donuts are oftentimes assessed for tumor cells, they are not
included in measurement of the distal margin of resection and therefore the true margin is
usually slightly larger than the distal margin of resection. Therefore, a margin reported and
measured as 5 mm may in fact be significantly larger, which helps explain why some patients
with low margins approaching 0 mm still seem to have acceptable oncologic outcomes.
In conclusion, in the era of neoadjuvant CRT, smaller distal margins are acceptable so long as
the overall status of the patient is considered as well as the possible behavior of the tumor.
Patients with well differentiated tumors who have achieved an excellent response to neoad‐
juvant CRT might only need negative margins. However, patients who have poorly differen‐
tiated tumors and no response to pre-operative CRT might need greater margins (greater or
equal to 1 cm). The distal margin is one of the few that the surgeon can correct and monitor
intra-operatively [40;64] and therefore ought to be a constant consideration for all surgeons
when performing a rectal resection. This must be done by balancing the desire for sphincter
preservation with the need to maintain an oncologically safe and thorough procedure.
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